Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 May 22;19(1):482.
doi: 10.1186/s12885-019-5688-z.

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma

Kailin Wang  1 , Jun Dong  2 , Shasha He  3 , Xia Wang  1 , Chang Jiang  2 , Pili Hu  2 , Jiangui Guo  4 , Xiuyu Cai  5 , Xicheng Wang  6
Affiliations
Comparative Study

Comparison of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy for nasopharyngeal carcinoma

Kailin Wang et al. BMC Cancer. .

Abstract

Background: We compared the survival outcomes and acute toxicities of weekly and triweekly cisplatin regimens during concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC) patients.

Methods: Patients were treated with CCRT alone. CCRT was initiated on the first day of RT. Cisplatin 30-40 mg/m2 was infused on days 1, 8, 15, 22, 29, 36 and 43 in the Weekly Group, while cisplatin 80-100 mg/m2 was delivered on days 1, 22 and 43 in the Triweekly Group. The survival outcomes were revealed by the Kaplan-Meier method and Cox regression modelling to measure 5-year overall survival (OS), disease-free survival (DFS), locoregional relapse-free survival (LRFS) and distant metastasis-free survival (DMFS).

Results: Ninety-three (28.9%) patients received three to 7 cycles of cisplatin weekly (Weekly Group) and 229 (71.1%) patients received two to 3 cycles of cisplatin triweekly (Triweekly Group). Five-year OS (weekly vs. triweekly, 96.7% vs. 88.3%, P = 0.036) and DFS (weekly vs. triweekly, 90.7% vs. 80.5%, P = 0.028) were better in the Weekly Group than in the Triweekly Group. The weekly vs. triweekly 5-year DMFS and LRFS rates were: DMFS, 96.7% vs. 91.4%, χ2 = 2.694, P = 0.101; LRFS, 96.3% vs. 93.5%, χ2 = 1.317, P = 0.251. Cisplatin delivery regimen was not an independent prognostic factor. The incidence rate of acute toxicities was similar between the groups.

Conclusions: Compared with Triweekly cisplatin regimen, Weekly regimen may be a better choice during CCRT.

Keywords: Cisplatin; Concurrent chemoradiotherapy; Nasopharyngeal carcinoma; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Survival curves for patients with NPC. The overall survival (OS) curves showed that the Weekly group was better than Triweekly group (P = 0.036, there was a significant difference between the groups) (a). The disease-free survival (DFS) curves showed that the Weekly group was better than the Triweekly group (P = 0.028, there was a significant difference between the groups) (b). The distant metastasis-free survival (DMFS) curves (c) and the locoregional relapse-free survival (LRFS) curves (d) revealed no significant difference between the two groups
Fig. 2
Fig. 2
Survival curves for patients with Stage-III–IVA NPC. The OS curves showed there was no significant difference between the two groups (a). The DFS curves showed that the Weekly group was better than the Triweekly group (P = 0.025, there was a significant difference between the groups) (b). The DMFS (c) and LRFS (d) curves showed no significant differences between the two groups
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Wei WI, Sham JS. Present status of management of nasopharyngeal carcinoma. Expert Rev Anticancer Ther. 2001;1(1):134–141. doi: 10.1586/14737140.1.1.134. - DOI - PubMed
    1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365(9476):2041–2054. doi: 10.1016/S0140-6736(05)66698-6. - DOI - PubMed
    1. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyama M, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):47–56. doi: 10.1016/j.ijrobp.2005.06.037. - DOI - PubMed
    1. He J, Wu P, Tang Y, Liu S, Xie C, Luo S, Zeng J, Xu J, Zhao S. Chemoradiotherapy enhanced the efficacy of radiotherapy in nasopharyngeal carcinoma patients: a network meta-analysis. Oncotarget. 2017;8(24):39782–39794. doi: 10.18632/oncotarget.16349. - DOI - PMC - PubMed

Publication types

LinkOut - more resources